7 Results for "

CP55

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "CP55" in MCE Product Catalog:

Cat. No.: HY-118140
CAS No.: 1998197-39-9
Purity:  99.43%
ZCZ011 is a potent and brain-penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .
loading...
    loading...
Cat. No.: HY-113421
CAS No.: 68171-52-8
Purity:  ≥98.0%
Synonyms: Linoleic acid monoethanolamide
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1(CB1)and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
loading...
    loading...
Cat. No.: HY-113421S
CAS No.: 1451194-69-6
Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1(CB1)and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
loading...
    loading...
Cat. No.: HY-174335
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

UVI3502 is a cannabinoid receptor 1 (CB1) antagonist with an IC50 value of 4641 nM for CB1 and approximately 16200 nM for CB2. UVI3502 blocks Gi/o protein coupling induced by the agonist CP55,940. UVI3502 is promising for research of endocannabinoid system-related diseases in the central nervous system (such as cognitive impairment and neurodegenerative diseases) .
loading...
    loading...
Cat. No.: HY-187995
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

RTICBM-303 is a blood-brain barrier-penetrant cannabinoid receptor type 1 (CB1) inhibitor. RTICBM-303 concentration-dependently decreases the Emax of the agonist CP55,940, increases the binding of [ 3H]CP55,940, and inhibits CB1 receptor signaling. RTICBM-303 selectively reduces cue-induced and drug-priming-induced drug-seeking relapse behaviors in rats. RTICBM-303 can be used in studies related to addictive behaviors .
loading...
    loading...
Cat. No.: HY-120093
CAS No.: 1663564-42-8
Research Areas:  

Neurological Disease

GAT100 is a negative allosteric modulator and covalent allosteric probe for cannabinoid receptor type 1 (CB1R). GAT100 acts as a positive allosteric modulator for orthosteric agonist CP55,940 binding to regulate the CB1R signaling pathway. GAT100 reduces the potency and efficacy of orthosteric CB1R agonists in terms of β-arrestin 1 recruitment, phosphorylation of PLCβ3 and ERK1/2, cAMP accumulation, and CB1R internalization. GAT100 is applicable to the research of psychobehavioral and somatic diseases .
loading...
    loading...
Cat. No.: HY-P7633
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD80; B-Lymphocyte Activation Antigen B7; Prev. CD28LG1; LAB7; Prev. CD28LG; BB1; T-Lymphocyte Activation Antigen CD80; B7; Activation B7-1 Antigen; Costimulatory Molecule Variant IgV-CD80; B7.1; Costimulatory Factor CD80; B7-1; CD80 Molecule; CD80 Antige
Species:  
Mouse
Source:  
HEK293
loading...
    loading...